Pharmaceuticals Archives - Page 2 of 45 - Healthcare Mumbai

Pharmaceuticals

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

March 18, 2024March 18, 2024Anette NilsenLeave a Comment

Pharmaceuticals

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

March 18, 2024March 18, 2024Sofie LarsenLeave a Comment

Pharmaceuticals

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

March 18, 2024March 18, 2024Kari HagenLeave a Comment

Pharmaceuticals

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

March 15, 2024March 15, 2024Leif KristoffersenLeave a Comment

Pharmaceuticals

Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes

March 14, 2024March 14, 2024Henrik OlsenLeave a Comment

Pharmaceuticals

Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

March 14, 2024March 14, 2024Sigrun PedersenLeave a Comment

Pharmaceuticals

Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland

March 13, 2024March 13, 2024Karin EriksenLeave a Comment

Pharmaceuticals

PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments

March 13, 2024March 13, 2024Staff ReporterLeave a Comment

Pharmaceuticals

Arctic Therapeutics and Nacuity Pharmaceuticals Announce European Medicines Agency Approval to Initiate First Clinical Trial of AT-001 (NPI-001) for the Treatment of HCCAA

March 12, 2024March 12, 2024Henrik OlsenLeave a Comment

Pharmaceuticals

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024

March 9, 2024March 9, 2024Staff ReporterLeave a Comment